Study of FX006 vs Normal Saline in Patients With Osteoarthritis of the Knee
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to assess the magnitude and duration of pain relief of a single
IA injection of 2 doses (16 and 32 mg) of FX006, an extended-release formulation of TCA,
relative to normal saline (placebo control).